TIME TO OPIOID USE AMONG COMMERCIALLY-INSURED PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS

被引：0

|

作者：

Zhao, Y. ^{[1
]}

Chen, S. Y. ^{[2
]}

Boulanger, L. ^{[2
]}

Fraser, K. ^{[2
]}

Wu, N. ^{[2
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN 46285 USA

[2] Abt Bio Pharma Solut Inc, Lexington, MA USA

来源：

VALUE IN HEALTH | 2010年 / 13卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)72303-2

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

收藏

页码：A65 / A65

页数：1

相关论文

共 32 条

[31] COMPARISON OF CHARACTERISTICS AND MEDICATION-ASSISTED TREATMENT (MAT)-RELATED HEALTHCARE RESOURCE UTILIZATION AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MAT RECEIVED
Perry, A.
Manjelievskaia, J.
VALUE IN HEALTH, 2019, 22 : S692 - S692
[32] HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY: IS INITIAL DOSING A SIGNIFICANT FACTOR?
Zhao, Y.
Boulanger, L.
Wu, N.
Lamothe, K.
Russell, M. W.
VALUE IN HEALTH, 2008, 11 (06) : A638 - A638

← 1 2 3 4 →